跳至主要内容
临床试验/NCT00684736
NCT00684736已完成不适用

Tryptophan, Serotonin and Kynurenine in Septic Shock

Versailles Hospital1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2004年6月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
30
试验地点
1
主要终点
Kinetics of 5-HT, 5-HIAA, kynurenine, tryptophan, HVA, VMA, DOPAC, Oestradiol, Cotinine and vasopressors

研究概览

简要总结

Septic shock is a major cause of mortality and morbidity worldwide. Serotonin (5-HT) is released by activated platelets into the circulation, and is mediator of endothelial dysfunction. 5-HT metabolism is known in immune system via specific 5-HT receptor, also in effects on the peripheral nervous system. Kinetic of 5-HT, tryptophan, kynurenine, MAO activity and IDO activity in human septic shock was never investigated.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age above or equal to 18 years
  • Strong presumption clinical sepsis
  • Need for mechanical ventilation
  • Body temperature above 38°C or below 36°C
  • Heart rate above 90 bpm
  • Systolic blood pressure of <90mm Hg despite adequate fluid replacement or a need for vasopressors less than 3 hours
  • Presence of at least one of the following criteria:
  • Ratio of arterial oxygen tension over inspired fraction of oxygen of less than 300 mm Hg
  • Urinary output below 0.5 mL per kg of bodyweight per h or below 30 mL/h (for at least 1 h)
  • Arterial lactate concentration above 2 mmol/L
  • Consent signed

排除标准

  • Age below 18 years
  • Pregnancy
  • Underlying disease with a poor prognosis, a life expectancy of less than 24 hours
  • Depression or melancholy
  • Neuropsychiatric diseases: Seizure, manic psychosis, Migraine, or Drug addiction
  • Neuroendocrine tumors
  • Obstructive cardiomyopathy or acute myocardial ischaemia
  • Pulmonary embolism
  • Advanced stage cancer, malignant haemopathy, or AIDS with a decision to withhold or withdraw aggressive therapies
  • Inclusion in another clinical trial
  • Patient who receive before inclusion one of the following treatment known to modify serotonin level: almotriptan, amitriptyline, amoxapine, citalopram, clomipramine, clozapine, desipramine, dihydroergotamine, dolasetron, dosulepin, doxepin, eletriptan, ergotamine, flunarizine, fluoxetine, fluvoxamine, granisetron, imipramine, indoramin, interferon Alfa, interferon alfacon-1, interferon beta, iproniazid, maprotiline, methysergide, mianserin, Milnacipran, mirtazapine, moclobemide, naratriptan, olanzapine, ondansetron, oxetorone, paroxetine, pizotifen, risperidone, sertraline, sumatriptan, tianeptine, trimipramine, tropisetron, venlafaxine,viloxazine, zolmitriptan.
  • No consent

结局指标

主要结局

Kinetics of 5-HT, 5-HIAA, kynurenine, tryptophan, HVA, VMA, DOPAC, Oestradiol, Cotinine and vasopressors

时间窗: Day-1, Day-2, Day-3, Day-7 and Day-14

次要结局

  • Mortality(28-day)

研究者

发起方
Versailles Hospital
申办方类型
Other

研究点 (1)

Loading locations...

相似试验